AUPH [NASD]
Aurinia Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.27 Insider Own0.30% Shs Outstand141.68M Perf Week1.34%
Market Cap1.56B Forward P/E- EPS next Y-0.14 Insider Trans-12.98% Shs Float132.77M Perf Month3.93%
Income-168.20M PEG- EPS next Q-0.22 Inst Own31.30% Short Float7.20% Perf Quarter-28.91%
Sales66.30M P/S23.48 EPS this Y-61.40% Inst Trans7.37% Short Ratio3.34 Perf Half Y-41.32%
Book/sh3.16 P/B3.59 EPS next Y88.40% ROA-37.50% Target Price23.81 Perf Year-19.60%
Cash/sh3.06 P/C3.72 EPS next 5Y- ROE-43.20% 52W Range8.86 - 33.97 Perf YTD-50.33%
Dividend- P/FCF- EPS past 5Y-16.20% ROI-37.90% 52W High-66.56% Beta1.01
Dividend %- Quick Ratio13.30 Sales past 5Y204.90% Gross Margin98.00% 52W Low28.22% ATR0.84
Employees300 Current Ratio14.10 Sales Q/Q-53.20% Oper. Margin- RSI (14)50.91 Volatility5.84% 8.34%
OptionableYes Debt/Eq0.00 EPS Q/Q32.80% Profit Margin- Rel Volume0.26 Prev Close11.31
ShortableYes LT Debt/Eq0.00 EarningsMay 10 BMO Payout- Avg Volume2.86M Price11.36
Recom1.60 SMA204.53% SMA50-0.97% SMA200-36.38% Volume751,299 Change0.44%
May-05-22Resumed Cantor Fitzgerald Overweight $34 → $25
Dec-10-21Upgrade Oppenheimer Perform → Outperform $33 → $31
Oct-28-21Downgrade Oppenheimer Outperform → Perform $32
Jan-25-21Reiterated H.C. Wainwright Buy $30 → $35
Nov-03-20Reiterated H.C. Wainwright Buy $34 → $28
Jun-17-20Initiated BTIG Research Buy $20
May-05-20Initiated Cowen Outperform
Jan-10-20Initiated Jefferies Buy $27
Dec-16-19Reiterated H.C. Wainwright Buy $25 → $32
Mar-16-18Reiterated Cantor Fitzgerald Overweight $14 → $16
Feb-08-18Initiated RBC Capital Mkts Outperform $9
Oct-30-17Reiterated H.C. Wainwright Buy $10 → $12
May-18-17Reiterated H.C. Wainwright Buy $12 → $10
Apr-11-17Initiated Cantor Fitzgerald Overweight $14
Mar-22-17Reiterated FBR & Co. Outperform $9 → $11
Dec-30-16Reiterated H.C. Wainwright Buy $10 → $8
Aug-17-16Reiterated H.C. Wainwright Buy $7 → $10
Jun-30-16Initiated H.C. Wainwright Buy $7
May-08-15Initiated MLV & Co Buy $9
May-20-22 12:07PM  
May-16-22 07:17AM  
May-10-22 07:15AM  
06:00AM  
May-06-22 04:05PM  
May-02-22 04:05PM  
04:00PM  
08:12AM  
Apr-28-22 03:02PM  
Apr-19-22 07:10AM  
Apr-04-22 04:11PM  
Mar-04-22 04:37AM  
Mar-03-22 04:31PM  
Mar-01-22 04:49AM  
Feb-28-22 04:28PM  
04:03PM  
09:43AM  
07:25AM  
06:00AM  
Feb-21-22 03:00PM  
Feb-10-22 04:33AM  
Feb-09-22 04:17PM  
Feb-03-22 07:05AM  
Jan-26-22 01:38PM  
Jan-21-22 01:38PM  
Jan-18-22 05:38PM  
Jan-13-22 05:38PM  
Jan-09-22 10:30AM  
Jan-04-22 04:17PM  
Dec-24-21 11:38PM  
05:02AM  
12:38AM  
Dec-20-21 09:57AM  
Dec-18-21 12:38AM  
Dec-13-21 03:14PM  
Dec-09-21 09:00AM  
06:15AM  
Dec-07-21 10:00AM  
Dec-03-21 10:11AM  
Dec-02-21 04:10PM  
02:13PM  
12:16PM  
Nov-22-21 04:32PM  
01:30PM  
11:51AM  
Nov-20-21 08:45AM  
Nov-19-21 08:34AM  
Nov-10-21 04:05PM  
Nov-09-21 12:14PM  
Nov-06-21 07:03AM  
Nov-03-21 03:31PM  
10:15AM  
07:15AM  
06:00AM  
Nov-01-21 10:12AM  
05:38AM  
Oct-27-21 09:04AM  
07:07AM  
Oct-26-21 04:10PM  
04:47AM  
Oct-25-21 04:17PM  
07:08AM  
Oct-24-21 10:15AM  
Oct-22-21 09:13PM  
05:38PM  
05:37PM  
04:11PM  
Sep-25-21 07:00AM  
Sep-20-21 09:02AM  
Sep-15-21 01:11PM  
10:40AM  
Sep-10-21 01:30PM  
Aug-27-21 02:50PM  
Aug-26-21 06:10AM  
Aug-18-21 10:24AM  
10:00AM  
Aug-17-21 04:09PM  
06:39AM  
06:05AM  
Aug-09-21 07:55AM  
Aug-07-21 04:27AM  
Aug-06-21 01:54PM  
09:30AM  
Aug-05-21 07:55PM  
04:05PM  
06:39AM  
Aug-04-21 08:40AM  
Jul-29-21 03:05PM  
Jul-26-21 06:05AM  
Jul-23-21 05:15PM  
Jul-16-21 05:30PM  
Jul-13-21 12:55PM  
Jun-30-21 07:05AM  
Jun-25-21 05:14AM  
Jun-23-21 01:53AM  
Jun-14-21 06:05AM  
Jun-07-21 07:05PM  
07:04AM  
May-27-21 06:05AM  
May-21-21 07:58AM  
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MacKay-Dunn R. HectorDirectorMar 09Buy11.005,00054,98511,000Mar 11 04:05 PM
MILNE GEORGE M JRDirectorMar 04Buy10.825,00054,10050,000Mar 08 04:06 PM
Donley Matthew MaxwellEx VP, Intern'l OperationsMar 02Sale12.013,05236,65516,224Mar 04 04:12 PM
Martin Michael RobertChief Business OfficerMar 02Sale12.014,84958,23659,512Mar 04 04:13 PM
Huizinga Robert BindertEVP of ResearchMar 02Sale12.014,84958,23669,379Mar 04 04:10 PM
Solomons NeilChief Medical OfficerMar 02Sale12.014,84658,20090,953Mar 04 04:10 PM
Greenleaf PeterChief Executive OfficerMar 02Sale12.019,068108,90732,967Mar 04 04:11 PM
Colao MassimilanoChief Commercial OfficerMar 02Sale12.013,20538,49213,495Mar 04 04:11 PM
Miller Joseph MChief Financial OfficerMar 02Sale12.013,06036,7516,610Mar 04 04:12 PM
Hagan Joseph PDirectorJan 03Option Exercise5.0840,000203,20043,500Jan 04 04:17 PM
Hagan Joseph PDirectorJan 03Sale22.5940,000903,6503,500Jan 04 04:17 PM
Leversage JillDirectorDec 13Buy20.041,60032,0645,300Dec 15 04:09 PM
Solomons NeilChief Medical OfficerNov 11Option Exercise5.30100,000530,000187,299Nov 12 04:13 PM
Martin Michael RobertChief Business OfficerNov 11Option Exercise18.3829,000533,02095,861Nov 12 04:18 PM
Martin Michael RobertChief Business OfficerNov 11Sale29.0140,0001,160,28055,861Nov 12 04:18 PM
Solomons NeilChief Medical OfficerNov 11Sale28.89100,0002,889,00087,299Nov 12 04:13 PM
Solomons NeilChief Medical OfficerNov 10Option Exercise5.83100,000583,200187,299Nov 12 04:13 PM
Solomons NeilChief Medical OfficerNov 10Sale31.11100,0003,110,80087,299Nov 12 04:13 PM
Martin Michael RobertChief Business OfficerNov 10Sale31.1460,0001,868,50066,861Nov 12 04:18 PM
Martin Michael RobertChief Business OfficerNov 09Sale30.1750,0001,508,500126,861Nov 12 04:18 PM
Solomons NeilChief Medical OfficerNov 09Sale30.1750,0001,508,50087,299Nov 12 04:13 PM
Martin Michael RobertChief Business OfficerNov 01Option Exercise3.2045,000144,000221,861Nov 03 04:20 PM
Solomons NeilChief Medical OfficerNov 01Option Exercise5.3045,000238,500182,299Nov 03 04:24 PM
Solomons NeilChief Medical OfficerNov 01Sale31.6445,0001,423,800137,299Nov 03 04:24 PM
Martin Michael RobertChief Business OfficerNov 01Sale31.6445,0001,423,800176,861Nov 03 04:20 PM
Huizinga Robert BindertEVP of ResearchOct 25Option Exercise3.2095,000304,000195,728Oct 26 04:33 PM
Huizinga Robert BindertEVP of ResearchOct 25Sale29.75130,0003,867,50065,728Oct 26 04:33 PM
Martin Michael RobertChief Business OfficerSep 21Option Exercise7.4087,500647,750264,361Sep 22 04:31 PM
Huizinga Robert BindertEVP of ResearchSep 21Option Exercise2.8627,13677,715133,228Sep 22 04:53 PM
Huizinga Robert BindertEVP of ResearchSep 21Sale23.9932,500779,533100,728Sep 22 04:53 PM
Martin Michael RobertChief Business OfficerSep 21Sale24.0287,5002,101,750176,861Sep 22 04:31 PM
Martin Michael RobertChief Business OfficerSep 20Option Exercise5.3028,500151,050205,361Sep 22 04:31 PM
Martin Michael RobertChief Business OfficerSep 20Sale21.6528,500616,975176,861Sep 22 04:31 PM
Martin Michael RobertChief Business OfficerSep 14Option Exercise4.2590,000382,500266,861Sep 14 06:16 PM
Martin Michael RobertChief Business OfficerSep 14Option Exercise5.3044,000233,200220,861Sep 16 05:01 PM
Martin Michael RobertChief Business OfficerSep 14Sale21.7844,000958,220176,861Sep 16 05:01 PM
Martin Michael RobertChief Business OfficerSep 14Sale21.1990,0001,907,217176,861Sep 14 06:16 PM
Huizinga Robert BindertEVP of ResearchSep 14Sale21.7522,500489,375106,092Sep 14 05:12 PM
Solomons NeilChief Medical OfficerSep 13Option Exercise3.20150,000480,000287,299Sep 14 05:11 PM
Martin Michael RobertChief Business OfficerSep 13Option Exercise5.3025,000132,500201,861Sep 14 06:16 PM
Martin Michael RobertChief Business OfficerSep 10Sale19.8025,000495,000176,861Sep 14 06:16 PM
Huizinga Robert BindertEVP of ResearchSep 10Sale19.8010,000197,950128,592Sep 14 05:12 PM
Solomons NeilChief Medical OfficerSep 10Sale19.84150,0002,976,000137,299Sep 14 05:11 PM
Martin Michael RobertChief Business OfficerSep 07Sale18.107,500135,750176,861Sep 08 04:04 PM
Huizinga Robert BindertEVP of ResearchSep 07Sale18.305,00091,500138,592Sep 08 04:03 PM
Martin Michael RobertChief Business OfficerAug 26Sale17.8122,500400,725184,361Aug 27 04:09 PM
Solomons NeilChief Medical OfficerAug 25Sale15.855,00079,250137,299Aug 26 04:15 PM
Solomons NeilChief Medical OfficerAug 09Sale16.0345,000721,350142,299Aug 10 04:11 PM
Martin Michael RobertChief Business OfficerAug 09Sale16.015,00080,050206,861Aug 10 04:09 PM
Martin Michael RobertChief Business OfficerJul 28Sale13.865,00069,300211,861Jul 29 04:09 PM
Martin Michael RobertChief Business OfficerJun 22Sale13.765,00068,800216,861Jun 23 04:06 PM